Correlation between cholinesterase inhibition and reduction in muscarinic receptors and choline uptake by repeated diisopropylfluorophosphate administration: antagonism by physostigmine and atropine.
Muscarinic receptors, [14C]choline uptake and acetylcholinesterase (AChE) activity in central and peripheral tissues of guinea-pigs treated repeatedly with diisopropylfluorophosphate (DFP) were simultaneously determined. After repeated DFP (1 mg/kg) administration, there was a significant decrease in specific [3H] quinuclidinyl benzilate binding only in the striatum, ileal longitudinal muscle and urinary bladder among various tissues examined. Scatchard analysis revealed that the administration of DFP at 0.5, 1 and 2 mg/kg which depressed the tissue AChE by 50 to 90%, caused a dose-dependent decrease (20-50%) in striatal and ileal [3H]quinuclidinyl benzilate binding sites without a change in the dissociation constant. The lower dose (0.2 mg/kg) of DFP depressed significantly the AChE in both tissues by 30% but failed to alter their [3H]quinuclidinyl benzilate binding sites. High affinity uptake of [14C]choline in the striatum and ileal longitudinal muscle was significantly decreased by repeated administration of DFP at 0.5 and 1 mg/kg but not 0.2 mg/kg. The DFP-induced loss of striatal and ileal muscarinic receptors was effectively antagonized by a concomitant administration of physostigmine (0.5 mg/kg) and atropine (5 mg/kg). Also, these drugs antagonized the DFP-induced decrease in the striatal [14C]choline uptake. Thus, the present study has demonstrated that repeated DFP administration causes a specific decrease in muscarinic receptors and [14C]choline uptake in the striatum and ileal longitudinal muscle of guinea pigs which is closely associated with a considerable (more than 50%) depression of the tissue AChE. In addition, these adaptive changes by DFP were effectively antagonized by physostigmine and atropine.
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D001285:Atropine / Q000494:pharmacology*; D002794:Choline / Q000378:metabolism*; D002800:Cholinesterase Inhibitors / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D006168:Guinea Pigs; D007531:Isoflurophate / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D009132:Muscles / Q000378:metabolism; D010830:Physostigmine / Q000494:pharmacology*; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D011950:Receptors, Cholinergic / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000378:metabolism*; D001743:Urinary Bladder / Q000378:metabolism
D002800:Cholinesterase Inhibitors; D011950:Receptors, Cholinergic; D011976:Receptors, Muscarinic; D007531:Isoflurophate; D011813:Quinuclidinyl Benzilate; D001285:Atropine; D010830:Physostigmine; D000110:Acetylcholinesterase; D002794:Choline